In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the ...

Lenalidomide Capsules are indicated for multiple myeloma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, and anemia of myelodysplastic syndromes (MDS) in adults. This was ...

For its part, Regeneron has studies on the go in mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL) and is also testing odronextamab alongside CD22xCD28 bispecific REGN5837 in aggressive ...

Regeneron has studies of odronextamab on the go in mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), and is also testing odronextamab in tandem with a CD22xCD28 bispecific REGN5837 in ...

On March 4, Biocon Pharma received final approvals for two key drug products: - Lenalidomide Capsules (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg), used for treating multiple myeloma, mantle cell ...

This type affects 1 in 20 people with lymphoma and is more common in older adults and men. It forms in your spleen, lymph nodes, or bone marrow. Mantle cell lymphoma grows slowly but can be hard ...

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

Lymphomas: CD is associated with classic Hodgkin lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and peripheral T-cell lymphoma. These associations are often IL-6 driven.

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...